

# A Comprehensive Evidence-Based Approach to Fever of Unknown Origin

Ophyr Mourad, MD, FRCPC; Valerie Palda, MD, MSc; Allan S. Detsky, MD, PhD

**Background:** Fever of unknown origin (FUO) is defined as a temperature higher than 38.3°C on several occasions and lasting longer than 3 weeks, with a diagnosis that remains uncertain after 1 week of investigation.

**Methods:** A systematic review was performed to develop evidence-based recommendations for the diagnostic workup of FUO. MEDLINE database was searched (January 1966 to December 2000) to identify articles related to FUO. Articles were included if the patient population met the criteria for FUO and they addressed the natural history, prognosis, or spectrum of disease or evaluated a diagnostic test in FUO. The quality of retrieved articles was rated as “good,” “fair,” or “poor,” and sensitivity, specificity, and diagnostic yield of tests were calculated. Recommendations were made in accordance with the strength of evidence.

**Results:** The prevalence of FUO in hospitalized patients is reported to be 2.9%. Eleven studies indicate that the spectrum of disease includes “no diagnosis” (19%), infections (28%), inflammatory diseases (21%), and malignancies (17%). Deep vein thrombosis (3%) and temporal

arteritis in the elderly (16%-17%) were important considerations. Four good natural history studies indicate that most patients with undiagnosed FUO recover spontaneously (51%-100%). One fair-quality study suggested a high specificity (99%) for the diagnosis of endocarditis in FUO by applying the Duke criteria. One fair-quality study showed that computed tomographic scanning of the abdomen had a diagnostic yield of 19%. Ten studies of nuclear imaging revealed that technetium was the most promising isotope, showing a high specificity (94%), albeit low sensitivity (40%-75%) (2 fair-quality studies). Two fair-quality studies showed liver biopsy to have a high diagnostic yield (14%-17%), but with risk of harm (0.009%-0.12% death). Empiric bone marrow cultures showed a low diagnostic yield of 0% to 2% (2 fair-quality articles).

**Conclusions:** Diagnosis of FUO may be assisted by the Duke criteria for endocarditis, computed tomographic scan of the abdomen, nuclear scanning with a technetium-based isotope, and liver biopsy (fair to good evidence). Routine bone marrow cultures are not recommended.

*Arch Intern Med.* 2003;163:545-551

From the Departments of Medicine (Drs Mourad, Palda, and Detsky) and Health Policy Management and Evaluation (Drs Palda and Detsky), University of Toronto; and the Division of General Internal Medicine, St Michael's Hospital (Drs Mourad and Palda) and Mt Sinai Hospital and University Health Network (Dr Detsky), Toronto, Ontario.

**F**EVER OF unknown origin (FUO) identifies a syndrome of fever that does not resolve spontaneously, in which the cause remains elusive after an extensive diagnostic workup. Petersdorf and Beeson<sup>1</sup> first coined the term *fever of unknown origin* in 1961 and explicitly defined it as a temperature higher than 38.3°C on several occasions and lasting longer than 3 weeks, with a diagnosis that remains uncertain after 1 week of investigations in hospital. Petersdorf and Beeson chose 3 weeks of fever to eliminate self-limited viral illnesses and to allow sufficient time for appropriate initial investigations to be completed. Over the past 40 years, health care has shifted from the inpatient to the ambulatory setting. As a result, it has now become widely accepted that the requirement for a 1-week evaluation in hospital be modified so that evaluations may now be completed in an outpatient setting.<sup>2</sup>

Fever of unknown origin is frustrating for patients and physicians because the diagnostic workup often involves numerous noninvasive and invasive procedures that sometimes fail to explain the fever. There are well over 200 different reported causes of FUO.<sup>3,4</sup> To date, there are no published guidelines or evidence-based recommendations for the diagnostic workup of FUO. The body of literature that discusses FUO comprises case series and cohort studies. In FUO, there is no diagnostic gold standard against which other diagnostic tests may be measured. Final diagnoses are determined in a number of ways, including natural history, biopsy, surgery, postmortem examinations as well as other imaging techniques. For these reasons, there is disagreement as to what should constitute a comprehensive diagnostic workup.

To have a structured, sensible, and effective approach, the clinician must have

an understanding of the spectrum of disease and the test characteristics of the various diagnostic modalities available in the evaluation of FUO. A rational approach should also be based on the relative frequencies of the different causes and their importance to the health of the patient. For the purpose of this article, FUO is not intended to encompass those individuals with impaired immunity or unexplained fevers in children. Fever of unknown origin in patients with human immunodeficiency virus infection, patients with known malignancy, and children have a different diagnostic differential and will not be addressed in this article.

## METHODS

MEDLINE database was searched to identify articles related to FUO. The search included English-language articles published between January 1966 to December 2000 using the Medical Subject Heading *fever of unknown origin* and the text words *FUO*, *PUO*, and *pyrexia of unknown origin*. Articles were included if the patient population was clearly defined and met the criteria set forth by Petersdorf and Beeson<sup>1</sup> for FUO and if they addressed the natural history, prognosis, or spectrum of disease or evaluated a diagnostic test in FUO. Articles were excluded if they focused on immunosuppressed patients, those younger than 18 years, and patients with human immunodeficiency virus infection or cancer. To identify a group of patients similar to our own, only patient populations from North America, Western Europe, and Scandinavia were included. A Cochrane review failed to identify any relevant articles. References of selected articles were reviewed to identify further relevant articles.

We define the diagnostic yield as the number of patients with positive test results divided by the number of all tested patients. The absolute value of the diagnostic yield should not be viewed independently, but rather together with information about the ability of the test to identify serious and potentially curable disease and all clinically important toxic effects of the diagnostic test.

## HARMS

Adverse effects of diagnostic tests were extracted from each individual study and from a separate literature review. MEDLINE database was searched for articles that identified complications and adverse effects of invasive diagnostic tests.

## SYSTEMATIC PROCESS USED TO ARRIVE AT FINAL RECOMMENDATIONS

Articles that met the selection criteria were summarized in tabular format. Criteria were developed to assess methodological quality for diagnostic tests and natural history studies based on published methods of the US Preventive Services Task Force.<sup>5</sup> The evidence was systematically reviewed by assigning a quality rating to each article according to a priori criteria. While the importance of research design remains the main basis by which to assess strength of evidence, not all studies within a research design have equal internal validity. To more clearly assess the internal validity of individual studies within research designs, design-specific criteria were used that allow rating of studies into 3 internal validity categories: "good," "fair," and "poor." Thus all individual studies receive 2 codes: 1 for research design and 1 (good, fair, poor) for internal validity within its design.

The body of evidence available for each topic was then synthesized, and recommendations were made based on the following considerations: published prevalence of disease, performance characteristics of the test (diagnostic yield, sensitivity, specificity, positive and negative likelihood ratios), harms of the test, strength of the evidence supporting the use of the test (study design and quality rating), and harms of the diagnostic test. For example, elements likely to result in a recommendation to perform the test would be good performance characteristics and no harms, even in the presence of limited evidence, or a test with moderate performance characteristics but multiple fair-quality studies demonstrating some benefit. Tests aimed at detecting common disorders were also more likely to be recommended. Final recommendations used language defined by The Canadian Task Force on Preventive Health Care, which was amended to apply to a diagnostic test.

Summary tables of the natural history, prognosis, and diagnostic studies as well as appendixes that describe criteria developed for study selection and assessment of the methodological quality of diagnostic tests and natural history studies are available on request from the authors.

## PREVALENCE AND SPECTRUM OF DISEASE

Ikuni et al<sup>6</sup> documented that of 5245 patients admitted to the Department of Internal Medicine between 1982 and 1992 at Kitasato University Hospital,

Kanagawa, Japan, 153 (2.9%) had FUO. Kazanjian<sup>7</sup> reported that of 6250 infectious disease consults performed at 3 community hospitals in Rhode Island between 1984 and 1990, 86 met the criteria for FUO (ie, 1 FUO in every 73 consults requested). Because FUO encompasses a wide spectrum of both infectious and noninfectious diseases, we believe that a significant proportion of patients will be investigated by general internists, with subspecialist (eg, infectious diseases, oncology, or rheumatology) consulting thereafter.

It is important to understand the spectrum of disease before addressing the utility of the diagnostic tools in the evaluation of FUO. The causes of FUO have traditionally been grouped into 1 of 4 categories: infectious, malignant, inflammatory, and undetermined.

There are 11 series that include over 1000 patients that have reported the diagnostic entities that constitute FUO.<sup>1,7-16</sup> Grouping all the patients collected from 1952 until 1994 reveals that the spectrum of disease includes infections in 28% and inflammatory diseases in 21%. Malignancies account for a smaller proportion (17%). A cause is never identified in a significant proportion (19%) of patients.

The spectrum of disease has also changed considerably from the time of the first prospectively collected series of 100 patients. Over the past 40 years, the proportion of cases of FUO caused by infections and neoplasms has decreased. The easy detection of solid tumors and abnormal lymph nodes via ultrasonography and computed tomography (CT) has resulted in the decline of tumors as a common cause of FUO, with the consequence that malignancies are less likely to present with prolonged undiagnosed fever. Patients with undiagnosed FUO used to make up the smallest proportion. At present, the largest proportion of patients who present with FUO never have a cause identified (**Figure 1**).

The most common infectious causes documented in the literature are tuberculosis and intra-abdominal abscesses.<sup>1,7,9,10,13,14</sup> The most common malignancies are Hodgkin disease and non-Hodgkin lymphoma.<sup>1,7,9,10,13,14</sup> Temporal arteritis accounts for 16% to 17% of all causes of FUO in the elderly.<sup>17,18</sup>

Outcomes of patients with FUO is a function of the underlying cause.<sup>1,7,10,12,13</sup> Overall, 12% to 35% of patients will die from FUO-related causes<sup>1,7,10,12,13</sup>; 52% to 100% of patients with a final diagnosis of malignancy will die within 5 years of the diagnosis.<sup>1,7,10,12</sup> Mortality is much lower if an infection is identified as the cause of FUO (8%-22%).<sup>1,7,10,12</sup> Therefore, the best predictor of survival is disease cat-

egory, with malignancy incurring the highest mortality. The prognosis of patients with FOU in whom a cause cannot be identified is excellent.<sup>1,6,10,13,19</sup> Most of these patients have a spontaneous recovery (51%-100%), and only a small proportion have persistent fever (0%-30%).

## RESULTS

### LIMITATIONS OF THE LITERATURE ON FOU

The body of literature that discusses FOU comprises case or cohort studies. There are no randomized controlled trials in the FOU literature. Most of these patients were identified in tertiary care centers; however, a number of studies report their experience from community hospitals.

### LIMITATIONS OF THE LITERATURE ON DIAGNOSTIC TESTS FOR FOU

In FOU, there is no diagnostic gold standard against which other diagnostic tests may be measured. Final diagnoses are determined in a number of ways, including natural history, biopsy, surgery, and post-mortem examinations as well as other imaging techniques. The diagnostic tests being assessed have been performed at various stages of the investigation. The definitions of true positives, false positives, true negatives, and false negatives vary from study to study. Therefore, calculation and significance of sensitivity, specificity, positive predictive value, negative predictive value, and likelihood ratios should be viewed with caution.

### INITIAL INVESTIGATIONS

Although there is no substitute for a thorough history review and physical examination, the yield from a complete history review and meticulous physical examination is not known, since it has never been studied. Review articles and articles evaluating a diagnostic test in FOU state explicitly that a certain number of investigations must be completed for a case to qualify as FOU. These have varied over the years, and we have compiled the following list




Figure 1. The percentage of patients with fever of unknown origin by cause over the past 40 years.

Table 1. Minimal Diagnostic Workup to Qualify as Fever of Unknown Origin

Comprehensive history
Physical examination
Complete blood cell count + differential
Blood film reviewed by hematopathologist
Routine blood chemistry (including lactic dehydrogenase, bilirubin, and liver enzymes)
Urinalysis and microscopy
Blood (×3) and urine cultures
Antinuclear antibodies, rheumatoid factor
Human immunodeficiency virus antibody
Cytomegalovirus IgM antibodies; heterophil antibody test (if consistent with mononucleosis-like syndrome)
Q-fever serology (if exposure risk factors exist)
Chest radiography
Hepatitis serology (if abnormal liver enzyme test result)

of minimum diagnostic evaluations based on reviewing all of the literature (Table 1).

One of the first steps that should be undertaken is to confirm that a true fever exists. Patients should be instructed to record and measure their temperature daily. The fever pattern adds little to the diagnostic workup.<sup>20</sup> Also, all medications should, if possible, be discontinued early in the evaluation to rule out a drug-induced fever. Persistence of fever beyond 72 hours after the suspected drug has been removed allows one to conclude that the drug is not the offending agent in producing the fever.<sup>21</sup>

### RECOMMENDED DIAGNOSTIC TESTS FOR WHICH EVIDENCE EXISTS

#### Abdominal CT

A CT of the abdomen should be one of the first investigations in FOU,

since it has a high diagnostic yield and is likely to identify 2 of the most common causes of FOU: intra-abdominal abscesses and lymphoproliferative disorders. A retrospective case series of an abdominal CT in the workup of FOU reported a diagnostic yield of 19%.<sup>22</sup> Clinical follow-up in 32 of the 47 cases in which the CT scan of the abdomen was normal identified only 1 patient with an intra-abdominal pathologic cause (lymphoma).

#### Nuclear Imaging

Ten studies of fair methodological quality have assessed the test characteristics of nuclear imaging studies in FOU.<sup>23-32</sup> Technetium (99m-Tc BW 250/183)-based studies report the highest specificity (93%-94%) but are insensitive (40%-75%).<sup>24,25</sup> Indium 111 IgG and indium 111-labeled white blood cell scans have poor sensitivity (45%-82%) and a specificity that ranges from 69% to

86%.<sup>26-30</sup> Gallium 67 nuclear scanning is less well studied.<sup>23,31,32</sup> The best quality study of gallium scanning reported a sensitivity of 67% and a specificity of 78% but only included 20 patients.<sup>23</sup> Fludeoxyglucose F 18 is a promising new alternative tracer that accumulates in both malignant tumors and at sites of inflammation. One recent small fair-quality study reported a sensitivity and specificity of 84% and 86% respectively.<sup>23</sup> Fludeoxyglucose F 18–based scans hold promise, but further studies are required to validate its utility.

Technetium (99m-Tc BW 250/183)–based scans are therefore most likely to be diagnostically helpful (positive likelihood ratio, 5.7–12.5) because of their high specificity (93%–94%). The other tests have been shown to be either poorly discriminating (gallium 67) or inconclusive because the studies were of poor overall quality.

The only potential toxic effect related to imaging studies such as CT and nuclear studies appears to be radiation exposure. The levels of radiation involved in nuclear medicine studies are usually considerably lower than a patient would receive in a conventional radiographic study or CT scan. Owing to its minimal toxicity and overall good test characteristics, nuclear imaging studies are helpful in localizing a potential infectious or inflammatory focus. Technetium should be the tracer of choice.

### The Duke Criteria

Infective endocarditis is an important cause of FUO and accounts for 1% to 5% of all causes.<sup>1,7,8,9,12-14</sup> The Duke criteria have a very high specificity in patients with FUO (99%; 95% confidence interval, 97%–100%), and thus should be used to identify patients with suspected infective endocarditis.<sup>33</sup> The design and retrospective nature of the study that assessed the utility of the Duke criteria in identifying those with infective endocarditis may have biased the results toward a higher specificity. Sensitivity data are more difficult to determine from the literature. The same authors determined that in 27 patients without FUO in whom the

diagnosis of infective endocarditis was histologically and/or bacteriologically confirmed, the sensitivity of the Duke criteria was 82%.<sup>34</sup>

### Liver Biopsy

The diagnostic yield from liver biopsy is 14% to 17%.<sup>35,36</sup> Physical examination findings of hepatomegaly or abnormal liver profile are not helpful in predicting which patients will have an abnormal liver biopsy result. In patients without FUO, complications from liver biopsies are reported in 0.06% to 0.32%.<sup>37-40</sup> Death as a direct result of the liver biopsy occurs in 0.009% to 0.12%. We believe that the benefits of a liver biopsy outweigh what we consider are minimal risks.

### Temporal Artery Biopsy

There is no single large series composed solely of elderly patients with FUO. Two studies (Esposito and Gleckman<sup>17</sup> and Knockaert et al<sup>18</sup>) identified temporal arteritis as the cause of FUO in 16% and 17%, respectively.<sup>17,18</sup> A decision analysis in the management of suspected giant cell arteritis concluded that a “biopsy and treat positive cases” is the preferred strategy when the likelihood of disease is intermediate.<sup>41</sup> Temporal artery biopsy is a safe surgical procedure<sup>42-44</sup> with rare complications including damage of the facial nerve,<sup>45</sup> skin necrosis,<sup>46</sup> and drooping of the eyebrow.<sup>47</sup> Color duplex ultrasonography of the temporal arteries may be a helpful alternative to temporal artery biopsy in the diagnosis of temporal arteritis, with a reported sensitivity and specificity of 93% when a halo, stenosis, or occlusion is identified.<sup>48</sup> Temporal arteritis accounts for a large proportion of causes of FUO in the elderly, and thus a temporal artery biopsy should be performed in elderly patients with unresolved FUO.

### Leg Doppler Imaging

Venous thrombosis can present with prolonged fever. Three series<sup>6,10,49</sup> reported a deep vein thrombosis as the cause of FUO in 2% to 6% of patients. Although deep vein thrombosis accounts for a small percentage of causes

of FUO, leg Doppler imaging is safe and may identify a treatable cause.

### DIAGNOSTIC TEST FOR WHICH EVIDENCE EXISTS TO RECOMMEND AGAINST: BONE MARROW CULTURES

The diagnostic yield of bone marrow cultures in immunocompetent individuals was found to be 0% to 2%.<sup>50,51</sup> Owing to the very low diagnostic yield from bone marrow cultures in FUO, bone marrow cultures are not recommended in the diagnostic workup. Physicians must use their discretion in determining whether there are other indications to perform a bone marrow biopsy.

### AREAS OF UNCERTAINTY

#### Surgical Exploration of the Abdomen

All of the studies reporting the diagnostic yield of exploratory laparotomy in FUO are of poor methodological quality. Most of the studies were performed in the pre-CT era,<sup>52-57</sup> whereas only 1 study examined the role of surgery in the post-CT era.<sup>58</sup> In that study, CT of the abdomen was performed in 14 of 25 patients, and 10 had abnormal findings on CT (hepatomegaly, splenomegaly, and/or retroperitoneal nodes). The diagnostic yield in those who had a normal CT and those who did not have a CT was not reported. The mortality rate was 4%, with 12% experiencing postoperative complications.

The diagnostic yield of laparoscopy was evaluated in 1 study in the pre-CT era and determined to be 44% with no mortality and minimal morbidity reported.<sup>59</sup> Liver biopsy was performed in 63 of 70 of these patients at laparoscopy, and it is not clear what proportion of final diagnoses were contributed to by the liver biopsy results alone. The role of surgery in the post-CT era remains unclear.

#### Empiric Therapy

The utility of empiric therapy, such as antibiotics, antituberculosis agents, or corticosteroids has not been studied in FUO. This, however, is not an uncommon practice

for the frustrated physician. We believe that empiric therapy should not be given to patients with FOU because it often obscures or confuses the diagnosis.

### COMMONLY PERFORMED DIAGNOSTIC TESTS FOR WHICH NO EVIDENCE EXISTS

There is no literature assessing the utility of erythrocyte sedimentation rate, C-reactive protein, magnetic resonance imaging, bone scan, and echocardiography in FOU.


Transthoracic echocardiography (sensitivity, 63%; specificity, 98%) and transesophageal echocardiography (sensitivity, 100%; specificity, 98%) may allow for early detection of vegetations on valves and may help to identify infective endocarditis.<sup>60</sup> Transesophageal echocardiography is important in the diagnosis of culture-negative endocarditis and performs better than transthoracic echocardiography.<sup>61</sup> The Duke criteria have incorporated echocardiography as an important tool in the diagnosis of endocarditis. It thus seems reasonable to include echocardiography in the diagnostic workup of FOU.

It is important to appreciate that there is no evidence to support or refute the utility of diagnostic tests such as echocardiography, magnetic resonance imaging, bone scan, and D-dimer assay in patients with FOU. Their potential utility may be extrapolated from the non-FOU literature.

### PROPOSED ALGORITHM

The proposed algorithm (**Figure 2**) was derived by taking into account the spectrum of disease, the clinical importance of the various causes, and the test characteristics of the various diagnostic modalities available in the evaluation of FOU. The procedures that were least invasive and those that reported the highest diagnostic yield appear early in the algorithm. Risks and complications of the various procedures were also taken into account. The algorithm was not derived through a formal process.

The proposed algorithm needs to be evaluated prospectively before its validity can be ascertained. Infor-



**Figure 2.** Proposed algorithm for an approach to fever of unknown origin (FUO). CT indicates computed tomography; DVT, deep vein thrombosis; IE, infective endocarditis; LMWH, low-molecular-weight heparin; TA, temporal artery; and Tc, technetium. See Table 1 for minimal diagnostic workup to qualify as FOU.

mation obtained from a thorough history review, repeated physical examinations, and initial laboratory studies may direct the physician to tests that do not conform to the algorithm. The algorithm is meant only as a framework, with necessary adjustments and provisions made according to pretest probability. The framework was derived from considerable evidence; however, one should not neglect the impact of the art of medicine and clinical experience on pretest probabilities, thus allowing for deviations from the proposed algorithm.

### CONCLUSIONS

The diagnostic workup of FOU remains complex; however, considerable evidence exists to guide empiric testing. Historically, the spectrum of disease includes “no diagnosis” (19%), infection (28%), inflammatory diseases (21%), and malignancies (17%), with deep vein thrombosis (3%) and temporal arteritis in the elderly (16%-17%) being important considerations. The diag-

nostic workup should begin with a thorough history review and physical examination. Routine noninvasive investigations (Table 1) are recommended in all patients prior to identifying a patient as having FOU. The Duke criteria have a very high specificity (99%) in patients with FOU and suspected infective endocarditis, and thus should be used to identify endocarditis as the cause of FOU. When the initial investigations are not helpful in identifying a cause, the clinician should then proceed to imaging. These should include a CT of the abdomen and a technetium-based nuclear scan. A CT of the abdomen has a high diagnostic yield (19%) and carries a low risk. Two fair-quality studies show that technetium-based scans have a high specificity but are insensitive. Leg Doppler imaging should be considered the next step in identifying deep vein thrombosis as a potential reversible and easily treatable cause. A temporal artery biopsy should be considered in elderly patients with FOU. There is fair evidence to suggest that

**Table 2. Recommendations for Diagnostic Testing in FUO**

Maneuver	Effectiveness*	Level of Evidence	Recommendation
The Duke criteria	Specificity = 99%	Fair (1 fair-quality study)	The Duke criteria has a very high specificity in patients with FUO and suspected infective endocarditis and thus should be used to identify endocarditis as the cause of FUO. (Recommend)
Abdominal CT	Diagnostic yield = 19% Sensitivity = 71% Specificity = 71%	Fair (1 fair-quality study)	A CT of the abdomen has a high diagnostic yield and is likely to contribute to identifying the cause of FUO. (Recommend)
Tc 99m BW 250/183 nuclear scan	Specificity = 93%-94% Sensitivity = 40%-75% +ve LR = 5.7-12.5	Fair (2 fair-quality studies)	Technetium-based scans have a high specificity and poor sensitivity. Technetium is the tracer of choice in the evaluation of FUO. (Recommend)
In 111 IgG nuclear scan	Specificity = 69%-79% Sensitivity = 47%-82%	Fair (1 fair- and 1 poor-quality study)	In 111 IgG-based scans have a poor sensitivity and specificity and are thus not the nuclear tracer of choice. (Recommend against)
In 111-labeled WBC scan	Specificity = 78%-86% Sensitivity = 45%-60% +ve LR = 2.7-3.2	Fair (1 fair- and 2 poor-quality studies)	In 111-labeled WBC scan is helpful in identifying suspected infectious processes. (Recommend)
Gallium 67 scan	Specificity = 70%-78% Sensitivity = 54%-67%	Fair (1 fair- and 1 poor-quality study)	Gallium-67-based scans have a poor sensitivity and specificity and are thus not the nuclear tracer of choice. (Recommend against)
ESR, C-reactive protein, MRI, echocardiography	...	...	There is no evidence to make recommendations for or against the use of ESR, C-reactive protein, MRI, bone scan, and echocardiography in the evaluation of FUO. (Insufficient evidence to recommend)
Empiric therapy	...	...	Empiric therapy with antibiotics, anti-TB agents, or corticosteroids should not be given to patients with FUO because they often obscure or confuse the diagnosis. (Insufficient evidence to recommend)
Liver biopsy	Diagnostic yield = 14%-17%	Fair (2 fair-quality studies)	Liver biopsy has a high diagnostic yield and minimal toxicity. (Recommend)
Bone marrow cultures	Diagnostic yield = 0%-2%	Fair (2 fair-quality studies)	Owing to the very low diagnostic yield from bone marrow cultures in FUO, bone marrow cultures are not recommended in the diagnostic workup. (Recommend against)
Laparotomy/laparoscopy	...	Poor (8 poor-quality studies)	Eight poor-quality studies revealed a high diagnostic yield in the pre-CT era. Surgical exploration of the abdomen is associated with significant morbidity and mortality. There are no studies evaluating the utility of surgical exploration in the post-CT era. (Insufficient evidence to recommend)

Abbreviations: CT, computed tomography; ESR, erythrocyte sedimentation rate; FUO, fever of unknown origin; In, indium; MRI, magnetic resonance imaging; TB, tuberculosis; Tc, technetium; WBC, white blood cell.

\*Diagnostic yield is defined as number of positive tests divided by the number of tests performed; +ve LR is sensitivity/1-specificity.

a liver biopsy has a high diagnostic yield with minimal toxicity. Bone marrow cultures are of low yield (0%-2%) and are not recommended in immunocompetent patients with FUO. The literature evaluating the role of laparoscopy and laparotomy is overall poor, and the risk of these interventions is high. These surgical procedures may be considered for individuals who have persistent fever and a deteriorating clinical course.

The role of erythrocyte sedimentation rate, C-reactive protein, magnetic resonance imaging, bone scan, and echocardiography has not been determined. The clinician must use judgment to determine whether these investigations would be of value for each individual patient (**Table 2**)

The prognosis of FUO is dependent on the etiological category. Undiagnosed FUO has a very favorable outcome. Patients in whom the above diagnostic investigations fail to identify a cause should be followed clinically with serial history reviews and physical examinations until the fever resolves or new diagnostic clues are found.

*Accepted for publication June 19, 2002.*

*No financial support was requested or rendered for this body of work.*

*We thank David McNeely, MD, and Hillar Vellend, MD, from the Divisions of Infectious Disease and General Internal Medicine, University Health Network, Toronto, Ontario, for reviewing the manuscript and providing valuable feedback.*

*Corresponding author: Ophyr Mourad, MD, Division of General Internal Medicine, St Michael's Hospital, Room 4-140, Cardinal Carter Wing, 30 Bond St, Toronto, Ontario, Canada M5B 1W8 (e-mail: MouradO@smh.toronto.on.ca).*

## REFERENCES

1. Petersdorf RG, Beeson P. Fever of unexplained origin: report on 100 cases. *Medicine (Baltimore)*. 1961;40:1-30.
2. Petersdorf RG. Fever of unknown origin: an old friend revisited. *Arch Intern Med*. 1992;152:21-22.
3. Arnow P, Flaherty J. Fever of unknown origin. *Lancet*. 1997;350:575-580.
4. Hirschmann JV. Fever of unknown origin in adults. *Clin Infect Dis*. 1997;24:291-300.
5. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. *Am J Prev Med*. 2001;3 (suppl):21-35.

6. Iikuni Y, Okada J, Kondo H, Kashiwazaki S. Current fever of unknown origin 1982-1992. *Intern Med.* 1994;33:67-73.
7. Kazanjian PH. Fever of unknown origin: review of 86 patients treated in community hospitals. *Clin Infect Dis.* 1992;15:968-973.
8. de Kleijn EM, van der Meer JW. Fever of unknown origin (FUO): report on 53 patients in a Dutch university hospital. *Neth J Med.* 1995;47:54-60.
9. Barbado FJ, Vazquez JJ, Pena JM, Arnalich F, Ortiz-Vazquez J. Pyrexia of unknown origin: changing spectrum of diseases in two consecutive series. *Postgrad Med J.* 1992;68:884-887.
10. Larson EB, Featherstone HJ, Petersdorf RG. Fever of undetermined origin: diagnosis and follow up of 105 cases, 1970-1980. *Medicine (Baltimore).* 1982;61:269-292.
11. Barbado FJ, Vazquez JJ, Pena JM, et al. Fever of unknown origin: a survey on 133 patients. *J Med.* 1984;15:185-192.
12. Deal WB. Fever of unknown origin: analysis of 34 patients. *Postgrad Med.* 1971;50:182-188.
13. de Kleijn EM, Vandenbroucke JP, van der Meer JM. Fever of unknown origin (FUO), IA: prospective multicenter study of 167 patients with FUO using fixed epidemiological criteria. *Medicine (Baltimore).* 1997;76:392-400.
14. Knockaert DC, Vanneste LJ, Vanneste SB, Bobbaers HJ. Fever of unknown origin in the 1980s: an update of the diagnostic spectrum. *Arch Intern Med.* 1992;152:51-55.
15. Smith JW. Southwestern Internal Medicine Conference: fever of undetermined origin: not what it used to be. *Am J Med Sci.* 1986;292:56-64.
16. Gleckman R, Crowley M, Esposito A. Fever of unknown origin: a view from the community hospital. *Am J Med Sci.* 1977;274:21-25.
17. Esposito AL, Gleckman RA. Fever of unknown origin in the elderly. *J Am Geriatr Soc.* 1978;26:498-505.
18. Knockaert DC, Vanneste LJ, Bobbaers HJ. Fever of unknown origin in elderly patients. *J Am Geriatr Soc.* 1993;41:1187-1192.
19. Knockaert DC, Dujardin KS, Bobbaers HJ. Long-term follow-up of patients with undiagnosed fever of unknown origin. *Arch Intern Med.* 1996;156:618-620.
20. Musher D, Fainstein V, Young EJ, Pruett TL. Fever patterns: their lack of clinical significance. *Arch Intern Med.* 1979;139:1225-1228.
21. Johnson DH, Cunha BA. Drug fever. *Infect Dis Clin North Am.* 1996;10:85-91.
22. Quinn MJ, Sheedy PF, Stephens DH, Haltery RR. Computed tomography of the abdomen in evaluation of patients with fever of unknown origin. *Radiology.* 1980;136:407-411.
23. Meller J, Altenuoerde G, Munzel U, et al. Fever of unknown origin: prospective comparison of [18F]FDG imaging with a double-head coincidence camera and gallium-67 citrate SPET. *Eur J Nucl Med.* 2000;27:1617-1625.
24. Meller J, Ivancevic V, Conrad M, Gratz S, Munz DL, Becker W. Clinical value of immunoscintigraphy in patients with fever of unknown origin. *J Nucl Med.* 1998;39:1248-1253.
25. Becker W, Dolkemeyer U, Gramatzki M, Schneider MU, Scheele J, Wolf F. Use of immunoscintigraphy in the diagnosis of fever of unknown origin. *Eur J Nucl Med.* 1993;20:1078-1083.
26. de Kleijn EM, Oyen W, Corstens F, van der Meer J. Utility of indium-111-labeled polyclonal immunoglobulin G scintigraphy in fever of unknown origin. *J Nucl Med.* 1997;38:484-489.
27. de Kleijn EM, Oyen W, Claessens R, Corstens F, van der Meer J. Utility of scintigraphic methods in patients with fever of unknown origin. *Arch Intern Med.* 1995;155:1989-1994.
28. MacSweeney JE, Peters AM, Lavender JP. Indium labeled leukocyte scanning in pyrexia of unknown origin. *Clin Radiol.* 1990;42:414-417.
29. Davies SG, Garvie NW. The role of indium-labeled leukocyte imaging in pyrexia of unknown origin. *Br J Radiol.* 1990;63:850-854.
30. Schmidt KG, Rasmussen JW, Sorensen PG, Wedebye IM. Indium-111-granulocyte scintigraphy in the evaluation of patients with fever of undetermined origin. *Scand J Infect Dis.* 1987;19:339-345.
31. Knockaert DC, Mortelmans A, De Roo MC. Clinical value of gallium-67 scintigraphy in evaluation of fever of unknown origin. *Clin Infect Dis.* 1994;18:601-605.
32. Knockaert DC, Mortelmans A, De Roo MC, Bobbaers HJ. Clinical value of gallium scintigraphy in the investigation of fever or inflammation of unknown origin in the ultrasound and computed tomography era. *Acta Clinica Belg.* 1989;44:91-98.
33. Hoen B, Beguinot I, Rabaud RJ, Selton-Suty C, May T, Canton P. The Duke criteria for diagnosing infective endocarditis are specific: analysis of 100 patients with acute fever or fever of unknown origin. *Clin Infect Dis.* 1996;23:298-302.
34. Hoen B, Selton-Suty C, Danchin N, et al. Evaluation of the Duke criteria versus the Beth Israel criteria for the diagnosis of infective endocarditis. *Clin Infect Dis.* 1995;21:905-909.
35. Mitchell DP, Hanes TE, Hoyumpa AM, Schenker S. Fever of unknown origin: assessment of the value of percutaneous liver biopsy. *Arch Intern Med.* 1977;137:1001-1004.
36. Holtz T, Moseley RH, Scheiman JM. Liver biopsy in fever of unknown origin: a reappraisal. *J Clin Gastroenterol.* 1993;17:29-32.
37. Tobkes A, Nord H. Liver biopsy: review of methodology and complications. *Dig Dis.* 1995;13:267-274.
38. Garcia-Tsao G, Boyer G. Outpatient liver biopsy: how safe is it? *Ann Intern Med.* 1993;118:150-153.
39. McGill D, Rakela J, Zinsmeister AR, Ott BJ. A 21 year experience with major hemorrhage after percutaneous liver biopsy. *Gastroenterology.* 1990;99:1396-1400.
40. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy: a multicenter retrospective study of 68,276 biopsies. *J Hepatol.* 1986;2:165-173.
41. Buchbinder R, Detsky AS. Management of suspected giant cell arteritis: a decision analysis. *J Rheumatol.* 1992;19:1220-1228.
42. Stuart RA. Temporal artery biopsy in suspected temporal arteritis: a five year survey. *N Z Med J.* 1989;102:431-433.
43. Kent RB III, Thomas L. Temporal artery biopsy. *Am Surg.* 1990;56:16-21.
44. Albertini JG, Ramsey ML, Marks VJ. Temporal artery biopsy in a dermatologic surgery practice. *Dermatol Surg.* 1999;25:501-508.
45. Scott KR, Tse DT, Kronish JW. Temporal artery biopsy technique: a clinico-anatomical approach. *Ophthalmic Surg.* 1991;22:519-525.
46. Siemssen SJ. On the occurrence of necrotizing lesions in temporal arteritis: review of the literature with a note on the potential risk of a biopsy. *Br J Plast Surg.* 1987;40:73-82.
47. Slavin ML. Brow droop after superficial temporal artery biopsy [letter]. *Arch Ophthalmol.* 1986;104:1127.
48. Schmidt WA, Kraft HE, Vorpahl K, Volker L, Gromnica-Ihle EJ. Color duplex ultrasonography in the diagnosis of temporal arteritis. *N Engl J Med.* 1997;337:1336-1342.
49. AbuRahma AF, Saiedy S, Robinson PA, Boland JP, Cotrell DJ IV, Stuart C. Role of venous duplex imaging of the lower extremities in patients with fever of unknown origin. *Surgery.* 1997;121:366-371.
50. Volk E, Miller ML, Kirskey BA, Washington JA. The diagnostic usefulness of bone marrow cultures in patients with fever of unknown origin. *Am J Clin Pathol.* 1998;110:150-153.
51. Riley U, Crawford S, Barrett SP, Abdalla SH. Detection of mycobacteria in bone marrow biopsy specimens taken to investigate pyrexia of unknown origin. *J Clin Pathol.* 1995;48:706-709.
52. Rothman DL, Schwartz SI, Adams JT. Diagnostic laparotomy for fever or abdominal pain of unknown origin. *Am J Surg.* 1977;133:273-275.
53. Howard PH Jr, Hardin WJ. The role of surgery in fever of unknown origin. *Surg Clin North Am.* 1972;52:397-403.
54. Barr J, Magnusson P, Wallensten S. Diagnostic laparotomy in cases of obscure fever. *Acta Chir Scand.* 1972;138:153-158.
55. Moossa AR, Skinner DB. The place of laparotomy in the management of pyrexia of unknown origin. *Ann R Coll Surg Engl.* 1972;51:396-401.
56. Ben-Shoshan M, Gius JA, Smith I. Exploratory laparotomy for fever of unknown origin. *Surg Gynecol Obstet.* 1971;132:994-996.
57. Keller JW, Williams RD. Laparotomy for unexplained fever. *Arch Surg.* 1965;90:494-498.
58. Takahashi T, Herrera MF, Onuma L, et al. Diagnostic laparotomy in fever of unknown origin. *Rev Invest Clin.* 1991;43:25-30.
59. Solis-Herruzo JA, Benita J, Morillas JD. Laparoscopy in fever of unknown origin—study of seventy cases. *Endoscopy.* 1981;13:207-210.
60. Erbel R, Rohmann S, Drexler M, Mohr-Kahaly S, Gerharz CD, Iversen S. Improved diagnostic value of echocardiography in patients with infective endocarditis by transesophageal approach: a prospective study. *Eur Heart J.* 1988;9:43-53.
61. Kuperwasser LI, Darius H, Muller AM, Martin C, Mohr-Kahaly S, Erbel R. Diagnosis of culture negative endocarditis: the role of the Duke criteria and the impact of transesophageal echocardiography. *Am Heart J.* 2001;142:146-152.